Plasma levels of apolipoprotein E, APOE genotype and risk of dementia and ischemic heart disease: A review

doi:10.1016/j.atherosclerosis.2016.10.037

Atherosclerosis

Volume 255, December 2016, Pages 145-155

https://doi.org/10.1016/j.atherosclerosis.2016.10.037 Get rights and content

Highlights

•
Apolipoprotein E (apoE) is implicated in both dementia and ischemic heart disease.
•
ApoE plays a pivotal role in lipoprotein metabolism in both brain and periphery.
•
ApoE plays both a qualitative and a quantitative role in these diseases.
•
The aim is to summarize the current evidence for plasma apoE in these diseases.

Abstract

Dementia is one of the major causes of disability in later life, and ischemic heart disease is a leading cause of morbidity and mortality. Apolipoprotein E (apoE) plays a pivotal role in lipoprotein metabolism in the brain and in the periphery, and is implicated in both dementia and ischemic heart disease.

Peripherally, liver-derived apoE is the main source of plasma apoE. Approximately half of plasma apoE is associated with triglyceride-rich lipoproteins, where apoE serves as the main ligand for the low density lipoprotein (LDL) receptor and the LDL receptor Related Protein (LRP). In the brain, apoE is produced mainly by astrocytes. Astrocyte-derived apoE is pivotal for cerebral cholesterol metabolism and clearance of β-amyloid, a major pathological hallmark of Alzheimer disease. Plasma levels of apoE and other lipids and lipoproteins are under strong genetic influence by the APOE polymorphism, and the ε4 allele is a strong genetic risk factor for Alzheimer disease. The characteristics of the APOE polymorphism thus suggest the qualitative importance of apoE, whereas studies of familial absolute apoE deficiency suggest a quantitative importance of plasma apoE levels in lipid metabolism. Whether plasma levels of apoE are associated with increased risk of dementia and ischemic heart disease, and whether these associations are independent of the APOE polymorphism and of lipids and lipoproteins has only recently been established.

The aim of this review is to summarize and discuss the current epidemiological and biological evidence for an association of plasma levels of apoE with risk of dementia and ischemic heart disease.

Introduction

Apolipoprotein E (apoE) plays a pivotal role in lipoprotein metabolism in the brain and in the periphery, and is implicated both in dementia and ischemic heart disease.

Alzheimer disease and other forms of dementia are devastating neurodegenerative diseases affecting ∼47 million people worldwide [1]. The evidence-based global prevalence is increasing, especially in low and middle income countries, with no currently available treatment [2]. For high income countries, the increase is more attenuated, and even declining trends have been found [3]. Ischemic heart disease is the leading cause of death worldwide [4]. Global deaths from cardiovascular disease are increasing and only in Central and Western Europe the annual number of death from cardiovascular disease has declined [5]. It has been estimated that approximately a third of Alzheimer disease cases may be attributable to potentially modifiable risk factors, whereas approximately 75% of all cardiovascular disease mortality might be prevented with adequate changes in lifestyle [6], [7]. Risk factors for dementia are generally not as well established and clear-cut as risk factors for ischemic heart disease, and, especially for interpretation of risk factors in dementia, this involves whether risk factors are evaluated in midlife or late life, which emphasizes that the possibility of reverse causation needs to be considered, and that the role of individual risk factors needs further exploration [8].

The apoE-associated lipid disorder ‘xanthoma tuberosum’ was first described by Gofman et al. in the 1950s [9]. Fredrickson et al. named it type III hyperlipoproteinemia in the 1960s, Havel and Kane described the involvement of apoE in the early 1970s, and Utermann et al. demonstrated that a particular isoform was involved [10], [11], [12]. The polymorphic nature of apolipoprotein E became evident in the late 1970s and early 1980s by Utermann, Zannis and Breslow, who refined the previous findings and proposed the now widely used nomenclature for the isoforms, genotypes and phenotypes [12], [13], [14]. Mahley et al. identified the amino acid structural differences among isoforms [15], [16], [17].

Plasma levels of apoE and other lipids and lipoproteins are under strong genetic influence by the APOE polymorphism defining the three apoE isoforms, and the ε4 allele is a strong genetic risk factor for Alzheimer disease [18], [19], [20], [21], [22], [23], [24], [25]. The characteristics of the APOE polymorphism thus suggest a qualitative importance of apoE, whereas studies of familial absolute apoE deficiency suggest a quantitative importance of plasma apoE levels in lipid metabolism [26], [27]. Whether plasma levels of apoE are associated with increased risk of dementia and ischemic heart disease in the general population, and whether these associations are independent of the APOE polymorphism and of lipids and lipoproteins has only recently been established.

The aim of this review is to summarize the current evidence of the importance of plasma levels of apoE for risk of dementia and ischemic heart disease. To provide the relevant context, the biology and metabolism of apoE and the currently implicated biomarkers are reviewed as well. A summary of common clinical biochemical biomarkers in dementia and ischemic heart disease is given in Table 1.

Section snippets

Gene structure of APOE

The APOE gene is located on chromosome 19 and consists of four exons [28]. Human apoE has three isoforms: apoE2, apoE3, and apoE4. Genetically, these isoforms correspond to three common alleles, ε2, ε3, and ε4, defined by two exonic single nucleotide polymorphisms (SNPs; rs429358/ε4, rs7412/ε2) in APOE [13], [29]. The two genotypes combine into six common APOE genotypes, ε22, ε32, ε42, ε33, ε43 and ε44, corresponding to six plasma apoE phenotypes: apoE22, apoE32, apoE42, apoE33, apoE43 and

Protein structure of apolipoprotein E

The mature apoE protein consists of 299 amino acids and an 18-amino acid signal peptide is removed post-translationally [17], [28]. Lipid-free apoE consists of two domains connected by a “hinge region”: the amino-terminal domain (amino acids 1 to 191) contains the receptor-binding function and the carboxyl-terminal domain (∼amino acids 225 to 299) contains the lipid-binding function [28], [33]. Both domains are highly helical, and as apoE consists mainly of amphipathic α-helixes, it forms a

Plasma levels of apolipoprotein E and APOE genotype, age and gender

Utermann et al. studied the association between levels of apoE in serum and the common APOE genotypes, and found that genotypes with the ε2 allele had highest and those with the ε4 allele had lowest average levels [20], [43]. Subsequently, it has been shown repeatedly that plasma levels of apoE are under strong genetic influence by the three common APOE alleles, ε2, ε3, and ε4 with stepwise decreases from ε22 to ε32 to ε42 to ε33 to ε43 to ε44 genotype [23], [44], [45], [46], [47], [48], [49],

Apolipoprotein E and lipid metabolism in the periphery

Peripherally, liver-derived apoE is the main source of apoE [9], [19]. Triglyceride-rich lipoproteins are causally associated with risk of ischemic heart disease and apoE plays a central role in their plasma clearance via receptor mediated uptake by the liver [9], [59]. Approximately half of plasma apoE is associated with triglyceride-rich lipoproteins, and apoE serves as the main ligand for the LDL receptor and LDL receptor Related Protein (LRP) [9], [60], [61]. Additionally, apoE plays a role

Apolipoprotein E and lipid metabolism in the brain

In the brain, apoE is mainly produced by astrocytes, although microglia and neurons can synthesize apoE under various physiological and pathological conditions [66], [67]. Stress-induced apoE synthesis by neurons is suggested to protect against injury and/or to promote regeneration [66], [68], [69], [70]. Recent in vitro studies have found that apoE4 expressed in neurons - but not in astrocytes - reduces the mitochondrial function [41]. ApoE protein expression has been found to differ among

Genetic variation in APOE and risk of dementia

The ε4 allele is a major genetic risk factor for late onset Alzheimer disease. This association was first recognized in 1993 by Corder et al., and has since been validated globally [25], [98]. The APOE polymorphism is by far the strongest genetic risk factor that has been implicated in common late-onset Alzheimer disease [99].

The APOE polymorphism affects risk of Alzheimer disease in a dose-dependent manner; the ε4 allele is associated with an increased risk and the ε2 allele is associated with

Plasma levels of apolipoprotein E and risk of dementia

Previously, some human studies of plasma or serum levels of apoE have found decreased levels in Alzheimer disease patients compared with control individuals, whereas other studies have reported that there was no differences [48], [49], [50], [103], [104]. Human studies of cerebrospinal fluid with various Alzheimer disease–related outcomes are conflicting, including differences in the APOE genotype stratified analyses [105], [106]. These conflicting observations may reflect that disease stages

Genetic variation in APOE and risk of ischemic heart disease

The biological mechanisms underlying the association between ε4 and plasma levels of apoE and other measures of lipid metabolism, and consequently, development of atherosclerosis and ischemic heart disease are not fully understood. The association between APOE genotype and risk of ischemic heart disease has been repeatedly investigated over the years. Lack of power and moderate per allele effects have challenged the interpretation of individual studies. In several meta-analyses, ε4 has been

Plasma levels of apolipoprotein E and risk of ischemic heart disease

In a population-based study of 546 elderly individuals, prospectively followed for specific causes of death for 5 years, high plasma levels of apoE were associated with increased cardiovascular mortality in both genders, independently of APOE genotype and plasma levels of triglycerides, LDL cholesterol and HDL cholesterol [44]. Other studies suggest that the increased cardiovascular risk associated with high plasma levels of apoE is limited to a subgroup of women with high C-reactive protein

Conclusions

The characteristics of the APOE polymorphism suggest a qualitative importance of apoE both for risk of dementia and for risk of ischemic heart disease.

A potential quantitative importance of plasma apoE for risk of dementia is emerging, supported by both animal studies and by epidemiological evidence. The quantitative relevance of apoE is important to be established, because the apoE level is discussed as a potential drug target [27], [34], [41], [87], [89], [110]. Further, reliable blood based

Conflict of interest

The author declared she does not have anything to disclose regarding conflict of interest with respect to this manuscript.

Acknowledgements

A warm thanks to Ruth Frikke-Schmidt for insightful comments. Furthermore, due to limitations in number of words and references and an extensive amount of contributions to the topics covered in this review from talented researchers worldwide, during many decades, a prioritization of the literature has been necessary.

References (127)

J.A. Finegold et al.
Mortality from ischaemic heart disease by country, region, and age: statistics from World Health Organisation and United Nations
Int. J. Cardiol.
(2013)
S. Norton et al.
Potential for primary prevention of Alzheimer's disease: an analysis of population-based data
Lancet Neurol.
(2014)
V.I. Zannis et al.
Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes
J. Lipid Res.
(1982)
K.H. Weisgraber et al.
Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms
J. Biol. Chem.
(1981)
S.C. Rall et al.
Human apolipoprotein E. The complete amino acid sequence
J. Biol. Chem.
(1982)
K.H. Weisgraber
Apolipoprotein E: structure-function relationships
Adv. Protein Chem.
(1994)
M.J. Artiga et al.
Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene
FEBS Lett.
(1998)
K.H. Weisgraber et al.
Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site
J. Biol. Chem.
(1982)
K.H. Weisgraber
Apolipoprotein E distribution among human plasma lipoproteins: role of the cysteine-arginine interchange at residue 112
J. Lipid Res.
(1990)
H.K. Chen et al.
Apolipoprotein E4 domain interaction mediates detrimental effects on mitochondria and is a potential therapeutic target for Alzheimer disease
J. Biol. Chem.
(2011)

D.M. Hatters et al.

Insight on the molecular envelope of lipid-bound apolipoprotein E from electron paramagnetic resonance spectroscopy

J. Mol. Biol.

(2009)

F. Schiele et al.

Apolipoprotein E serum concentration and polymorphism in six European countries: the ApoEurope Project

Atherosclerosis

(2000)

R. Simon et al.

Total ApoE and ApoE4 isoform assays in an Alzheimer's disease case-control study by targeted mass spectrometry (n=669): a pilot assay for methionine-containing proteotypic peptides

Mol. Cell Proteomics

(2012)

R. Scacchi et al.

Plasma levels of apolipoprotein E and genetic markers in elderly patients with Alzheimer's disease

Neurosci. Lett.

(1999)

A.J. Slooter et al.

Serum apolipoprotein E level is not increased in Alzheimer's disease: the Rotterdam study

Neurosci. Lett.

(1998)

N.R. Phillips et al.

Sex-related differences in the concentrations of apolipoprotein E in human blood plasma and plasma lipoproteins

J. Lipid Res.

(1983)

N. Rifai et al.

A simple immunotechnique for the determination of serum concentration of apolipoprotein E

Clin. Chim. Acta

(1987)

Y.P. Au et al.

A rapid apolipoprotein E radioimmunoassay using solid-phase staphylococcus protein. Use of pooled plasma as a secondary standard

Biochem. Biophys. Res. Commun.

(1986)

B.G. Nordestgaard et al.

Triglycerides and cardiovascular disease

Lancet

(2014)

T.P. Bersot et al.

Interaction of swine lipoproteins with the low density lipoprotein receptor in human fibroblasts

J. Biol. Chem.

(1976)

Y. Huang et al.

Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia

J. Biol. Chem.

(1998)

J. Kim et al.

The role of apolipoprotein E in Alzheimer's disease

Neuron

(2009)

R.E. Pitas et al.

Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins

Biochim. Biophys. Acta

(1987)

L.T. Nordestgaard et al.

Loss-of-function mutation in ABCA1 and risk of Alzheimer's disease and cerebrovascular disease

Alzheimers Dement.

(2015)

R.W. Mahley et al.

Apolipoprotein e sets the stage: response to injury triggers neuropathology

Neuron

(2012)

K. Nishitsuji et al.

Apolipoprotein E regulates the integrity of tight junctions in an isoform-dependent manner in an in vitro blood-brain barrier model

J. Biol. Chem.

(2011)

R.B. DeMattos et al.

ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo

Neuron

(2004)

P. Lohse et al.

Familial apolipoprotein E deficiency and type III hyperlipoproteinemia due to a premature stop codon in the apolipoprotein E gene

J. Lipid Res.

(1992)

P.B. Verghese et al.

Apolipoprotein E in Alzheimer's disease and other neurological disorders

Lancet Neurol.

(2011)

World Alzheimer Report 2015. The Global Impact of Dementia. An Analysis of Prevalence, Incidence, Cost and Trends

(2015)

M. Prince et al.

The global prevalence of dementia: a systematic review and metaanalysis

Alzheimers Dement.

(2013)

C.L. Satizabal et al.

Incidence of dementia over three decades in the Framingham heart study

N. Engl. J. Med.

(2016)

G.A. Roth et al.

Demographic and epidemiologic drivers of global cardiovascular mortality

N. Engl. J. Med.

(2015)

J. Perk et al.

European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)

Eur. Heart J.

(2012)

World Alzheimer Report 2014. Dementia and Risk Reduction. An Analysis of Protective and Modifiable Factors

(2014)

R.W. Mahley et al.

Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism

D.S. Fredrickson et al.

Fat transport in lipoproteins–an integrated approach to mechanisms and disorders

N. Engl. J. Med.

(1967)

R.J. Havel et al.

Primary dysbetalipoproteinemia: predominance of a specific apoprotein species in triglyceride-rich lipoproteins

Proc. Natl. Acad. Sci. U. S. A.

(1973)

G. Utermann et al.

Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man

Nature

(1977)

V.I. Zannis et al.

Human apolipoprotein E isoprotein subclasses are genetically determined

Am. J. Hum. Genet.

(1981)

S.C. Rall et al.

Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects

Proc. Natl. Acad. Sci. U. S. A.

(1982)

A.M. Bennet et al.

Association of apolipoprotein E genotypes with lipid levels and coronary risk

JAMA

(2007)

C.F. Sing et al.

Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation

Am. J. Hum. Genet.

(1985)

E. Boerwinkle et al.

Simultaneous effects of the apolipoprotein E polymorphism on apolipoprotein E, apolipoprotein B, and cholesterol metabolism

Am. J. Hum. Genet.

(1988)

M. Smit et al.

Apolipoprotein E polymorphism in The Netherlands and its effect on plasma lipid and apolipoprotein levels

Hum. Genet.

(1988)

M.C. Neale et al.

ApoE polymorphism accounts for only part of the genetic variation in quantitative ApoE levels

Genet. Epidemiol.

(2000)

K.L. Rasmussen et al.

Plasma levels of apolipoprotein E and risk of dementia in the general population

Ann. Neurol.

(2015)

J. Davignon et al.

Apolipoprotein E polymorphism and atherosclerosis

Arteriosclerosis

(1988)

E.H. Corder et al.

Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families

Science

(1993)

E.J. Schaefer et al.

Familial apolipoprotein E deficiency

J. Clin. Investig.

(1986)

Cited by (82)

APOE and vascular disease: Sequencing and genotyping in general population cohorts
2023, Atherosclerosis
The apolipoprotein E(APOE) ϵ2/ϵ3/ϵ4 polymorphism plays a central role in lipid metabolism, vascular disease and dementia. The impact of the full range of structural genetic variation in APOE for lipids, lipoproteins and apolipoproteins and for vascular disease in the general population is not known.
We systematically sequenced APOE in 10,296 individuals from the Copenhagen City Heart Study and genotyped nine rare variants (frequency≥2/10,296) in 95,227 individuals from the Copenhagen General Population Study. The UK Biobank was used for validation of common APOE variants.
Rare mutations in APOE, predicted to be deleterious, are present in 1 in 257 individuals in the general population. In the meta-analysis, multifactorially adjusted hazard ratios (95% confidence intervals) for ϵ44 and ϵ22 versus ϵ33 were 1.15 (1.04–1.26) and 1.02 (0.83–1.24) for ischemic cerebrovascular disease (ICVD), 1.11 (1.04–1.19) and 0.94 (0.83–1.08) for ischemic heart disease (IHD) and 1.03 (0.89–1.17) and 1.49 (1.20–1.87) for peripheral arterial disease (PAD). A multifactorially and ϵ2/ϵ3/ϵ4 adjusted weighted allele score on the continuous scale including all common and rare structural variants showed that for individuals with genetically predicted high plasma apoE and remnant cholesterol the risk for PAD was increased.
APOE variants with high apoE, triglycerides, and remnant cholesterol are associated with PAD, whereas common APOE variants with high LDL cholesterol, triglycerides and remnant cholesterol are associated with IHD. APOE variants with low apoE are associated with increased risk of ICVD. These findings highlight that both rare and common structural variations in APOE play a role in vascular disease.
Protective effect of probiotic Limosilactobacillus reuteri DSM17938 against western diet-induced obesity and associated metabolic alterations
2023, Journal of Functional Foods
To evaluate the possible application of Limosilactobacillus reuteri DSM 17938 as a strategy to prevent Western Diet-induced metabolic alterations and liver dysfunction.
Male Wistar rats of 90 days were divided in three groups and fed a control diet (CD), a high fat - high fructose diet alone (WD) or in combination with the administration of 10⁸ CFU of L. reuteri (WD-R) for 8 weeks. Body composition, energy balance and plasma lipid profile were evaluated, together with hepatic glucose homeostasis and insulin sensitivity. Metabolic inflammation was also assessed at a whole-body level and in the liver, together with mitochondrial function and oxidative stress.
Rats that received the WD and L. reuteri administration exhibited a lower body lipid gain and a higher protein gain, underlying a beneficial effect of the probiotic in counteracting the development of obesity. Moreover, the WD-R rats were protected from the development of inflammation at a whole body and liver level and displayed normal glucose homeostasis and insulin sensitivity, a decreased hepatic lipid deposition and a preserved function of the mitochondrial respiratory chain and redox balance.
We demonstrate for the first time that Limosilactobacillus reuteri DSM 17938 has a strong efficacy in preventing the development of the hepatic metabolic derangement elicited by the Western diet administration. These are promising results that open the way for the use of this probiotic as a prevention strategy against the development of diet-related diseases, such as type two diabetes and metabolic syndrome.
Apolipoprotein E is required for brain iron homeostasis in mice
2023, Redox Biology
Apolipoprotein E deficiency (ApoE^−/−) increases progressively iron in the liver, spleen and aortic tissues with age in mice. However, it is unknown whether ApoE affects brain iron.
We investigated iron contents, expression of transferrin receptor 1 (TfR1), ferroportin 1 (Fpn1), iron regulatory proteins (IRPs), aconitase, hepcidin, Aβ42, MAP2, reactive oxygen species (ROS), cytokines and glutathione peroxidase 4 (Gpx4) in the brain of ApoE^−/− mice.
We demonstrated that ApoE^−/− induced a significant increase in iron, TfR1 and IRPs and a reduction in Fpn1, aconitase and hepcidin in the hippocampus and basal ganglia. We also showed that replenishment of ApoE absent partly reversed the iron-related phenotype in ApoE^−/− mice at 24-months old. In addition, ApoE^−/− induced a significant increase in Aβ42, MDA, 8-isoprostane, IL-1β, IL-6, and TNFα and a reduction in MAP2 and Gpx4 in hippocampus, basal ganglia and/or cortex of mice at 24-months old.
Our findings implied that ApoE is required for brain iron homeostasis and ApoE^−/−-induced increase in brain iron is due to the increased IRP/TfR1-mediated cell-iron uptake as well as the reduced IRP/Fpn1 associated cell-iron export and suggested that ApoE^−/− induced neuronal injury resulted mainly from the increased iron and subsequently ROS, inflammation and ferroptosis.
Establishment of a lipid metabolism disorder model in ApoEb mutant zebrafish
2022, Atherosclerosis
Citation Excerpt :
The relationship between ApoE and the risk of cardiovascular diseases (CVDs) such as hyperlipidemia and ischemic heart disease has been discovered through numerous epidemiological observational and genetics studies, as well as interventional clinical trials [3]. Approximately half of plasma ApoE is associated with triglyceride-rich lipoproteins, where ApoE serves as the main ligand for the low-density lipoprotein receptor (LDLR) and the LDLR-related protein (LRP) [3]. Previous studies found that the sterol-regulatory element binding protein (SREBP) regulates the expression of LDLR and other proteins involved in the biosynthesis of cholesterol like hydroxy-3-methyl glutaryl coenzyme A reductase (HMGCR) [4], fatty acid synthase (FASN) [5] and proprotein convertase subtilisin/kexin type 9 (PCSK9) [6].
ApoEb is a zebrafish homologous to mammalian ApoE, whose deficiency would lead to lipid metabolism disorders (LMDs) like atherosclerosis. We attempted to knock out the zebrafish ApoEb, then establish a zebrafish model with LMD.
ApoEb was knocked out using the CRISPR/Cas9 system, and the accumulation of lipids was confirmed by Oil Red O staining, confocal imaging, and lipid measurements. The lipid-lowering effects of simvastatin (SIM), ezetimibe (EZE) and Xuezhikang (XZK), an extract derived from red yeast rice, were evaluated through in vivo imaging in zebrafish larvae.
In the ApoEb mutant, significant vascular lipid deposition occurred, and lipid measurement performed in the whole-body homogenate of larvae and adult plasma showed significantly increased lipid levels. SIM, EZE and XZK apparently relieved hyperlipidemia in ApoEb mutants, and XZK had a significant inhibitory effect on the recruitment of neutrophils and macrophages.
In this study, an LMD model has been established in ApoEb mutant zebrafish. We suggest that this versatile model could be applied in studying hypercholesterolemia and related vascular pathology in the context of early atherosclerosis, as well as the physiological function of ApoE.
Moderate ethanol exposure reduces astrocyte-induced neuroinflammatorysignaling and cognitive decline in presymptomatic APP/PS1 mice
2023, Research Square
Plasma apolipoprotein E levels, isoform composition, and dimer profile in relation to plasma lipids in racially diverse patients with Alzheimer’s disease and mild cognitive impairment
2023, Alzheimer's Research and Therapy

View all citing articles on Scopus

View full text

Review articlePlasma levels of apolipoprotein E, APOE genotype and risk of dementia and ischemic heart disease: A review

Highlights

Abstract

Introduction

Section snippets

Gene structure of APOE

Protein structure of apolipoprotein E

Plasma levels of apolipoprotein E and APOE genotype, age and gender

Apolipoprotein E and lipid metabolism in the periphery

Apolipoprotein E and lipid metabolism in the brain

Genetic variation in APOE and risk of dementia

Plasma levels of apolipoprotein E and risk of dementia

Genetic variation in APOE and risk of ischemic heart disease

Plasma levels of apolipoprotein E and risk of ischemic heart disease

Conclusions

Conflict of interest

Acknowledgements

Int. J. Cardiol.

Lancet Neurol.

J. Lipid Res.

J. Biol. Chem.

J. Biol. Chem.

Adv. Protein Chem.

FEBS Lett.

J. Biol. Chem.

J. Lipid Res.

J. Biol. Chem.

J. Mol. Biol.

Atherosclerosis

Mol. Cell Proteomics

Neurosci. Lett.

Neurosci. Lett.

J. Lipid Res.

Clin. Chim. Acta

Biochem. Biophys. Res. Commun.

Lancet

J. Biol. Chem.

J. Biol. Chem.

Neuron

Biochim. Biophys. Acta

Alzheimers Dement.

Neuron

J. Biol. Chem.

Neuron

J. Lipid Res.

Lancet Neurol.

World Alzheimer Report 2015. The Global Impact of Dementia. An Analysis of Prevalence, Incidence, Cost and Trends

The global prevalence of dementia: a systematic review and metaanalysis

Alzheimers Dement.

Incidence of dementia over three decades in the Framingham heart study

N. Engl. J. Med.

Demographic and epidemiologic drivers of global cardiovascular mortality

N. Engl. J. Med.

Eur. Heart J.

World Alzheimer Report 2014. Dementia and Risk Reduction. An Analysis of Protective and Modifiable Factors

Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism

Fat transport in lipoproteins–an integrated approach to mechanisms and disorders

N. Engl. J. Med.

Primary dysbetalipoproteinemia: predominance of a specific apoprotein species in triglyceride-rich lipoproteins

Proc. Natl. Acad. Sci. U. S. A.

Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man

Nature

Human apolipoprotein E isoprotein subclasses are genetically determined

Am. J. Hum. Genet.

Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects

Proc. Natl. Acad. Sci. U. S. A.

Association of apolipoprotein E genotypes with lipid levels and coronary risk

JAMA

Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation

Am. J. Hum. Genet.

Simultaneous effects of the apolipoprotein E polymorphism on apolipoprotein E, apolipoprotein B, and cholesterol metabolism

Am. J. Hum. Genet.

Apolipoprotein E polymorphism in The Netherlands and its effect on plasma lipid and apolipoprotein levels

Hum. Genet.

ApoE polymorphism accounts for only part of the genetic variation in quantitative ApoE levels

Genet. Epidemiol.

Plasma levels of apolipoprotein E and risk of dementia in the general population

Ann. Neurol.

Apolipoprotein E polymorphism and atherosclerosis

Arteriosclerosis

Review article
Plasma levels of apolipoprotein E, APOE genotype and risk of dementia and ischemic heart disease: A review